Aptamer Sciences Inc.
Financials
Valuation Metrics
Aptamer Sciences Inc.'s Market Cap is ₩794B. At end of 2025 it was ₩463B. Ranked #1416 of 2,410 in KR market (top 59%), #800 of 1,631 on KOSDAQ (top 49%), #154 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 67%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 79.35B KRW | KR#1,416/2,410 Sec#154/231 |
| Revenue | 5.40B KRW | KR#2,326/2,410 Sec#193/231 |
| Net Income | -11.65B KRW | KR—/2,410 Sec—/231 |
| Total Assets | 68.55B KRW | KR#2,020/2,410 Sec#166/231 |
| Net Assets | 42.25B KRW | KR#2,011/2,410 Sec#174/231 |
| Employees | 55 | KR#2,006/2,410 Sec#184/231 |
| Value | ||
| P/B | 1.88x | KR#1,905/2,410 Sec#141/231 |
| P/S | 14.70x | KR#2,310/2,410 Sec#177/231 |
| FCF Yield | -12.21% | KR—/2,410 Sec—/231 |
| Profitability | ||
| ROE | -27.57% | KR#2,151/2,410 Sec#170/231 |
| ROA | -17.00% | KR#2,206/2,410 Sec#171/231 |
| Op. Margin | -159.14% | KR#2,315/2,410 Sec#183/231 |
| Revenue Growth | 143.57% | KR#57/2,410 Sec#11/231 |
| Financial Health | ||
| Debt Ratio | 62.23% | KR#1,119/2,410 Sec#132/231 |
| Total Debt | 13.90B KRW | KR#1,512/2,410 Sec#131/231 |
| FCF | -9.69B KRW | KR#1,693/2,410 Sec#147/231 |
| Cash | 17.89B KRW | KR#1,310/2,410 Sec#101/231 |
| Current Ratio | 1.27x | KR#1,422/2,410 Sec#151/231 |
| Performance | ||
| 1Y Return | 39.63% | KR#317/2,410 Sec#19/231 |
| 1M Return | 4.00% | KR#158/2,410 Sec#13/231 |
| From 52W High | -34.93% | KR#736/2,410 Sec#49/231 |
| 1Y MDD | -64.45% | KR#1,687/2,410 Sec#140/231 |
| Trading | ||
| Volume | 214,267 shares | KR#1,468/2,410 Sec#147/231 |
| Trading Value | 555.4M KRW | KR#1,737/2,410 Sec#185/231 |
| Foreign Own. | 20.07% | KR#227/2,410 Sec#11/231 |
| Per Share | ||
| EPS | -382 KRW | KR—/2,410 Sec—/231 |
| BPS | 1,384 KRW | KR#2,223/2,410 Sec#195/231 |
Company Info
Aptamer Sciences, established in 2011 as a POSTECH spin-off, listed on KOSDAQ in 2020 and expanded into the Contract Research Organization (CRO) business by acquiring ISS in 2024. The company is developing solid and blood cancer therapeutics leveraging its aptamer technology platform, with its flagship product, Aptodetect Lung, being an excellent in-vitro diagnostic kit. Aptamer Sciences is further building expertise in biopharmaceutical analysis and establishing a comprehensive new drug development system to advance next-generation anticancer drug development.